Arun K. Shukla

This paper identifies abemaciclib, an FDA-approved CDK4/6 inhibitor, as a potent agonist of ACKR3, an atypical chemokine receptor, revealing its ability to modulate chemokine availability and receptor activity.

This paper identifies naturally-encoded signaling bias at C5aR1 and C5aR2 receptors through structural and functional analyses, revealing molecular mechanisms underlying biased signaling in GPCRs.

This study determines the cryo-EM structures of DARC bound to chemokines CCL7 and CXCL8, revealing unique binding mechanisms and the role of tyrosine sulfation and allelic variation in chemokine engagement.

This study reveals an atypical activation mechanism of CXCR7, identifies its role as an opioid receptor, and highlights potential for novel pain therapeutics.

This study introduces a nanobody sensor to detect conformational changes in beta-arrestins upon GPCR activation, revealing receptor-specific conformational diversity.

This study identifies a convergent molecular mechanism and species-specific pharmacology in complement anaphylatoxin receptors through structural and functional analyses of ligand-receptor interactions.

This paper presents computational methods for designing GPCR-binding miniproteins and validates them through high-throughput screening, producing agonists and antagonists for multiple GPCRs.

This study investigates ligand promiscuity and signaling bias in chemokine receptors by analyzing binding modes and determining cryo-EM structures of receptor-ligand complexes.

This paper determines the cryo-EM structure of the β1AR-βarr1 complex bound to formoterol and compares it to the β1AR-Gs complex, revealing structural differences that inform biased agonism.